Top Markets
Coin of the day
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rank in Stocks #33997
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Share Price
$0.1502
Last synced: 2024-11-04
Market Cap
$6.43M
Change (1 day)
-5.45%
Change (1 year)
0.00%
Country
US
Trade Renalytix Plc (RNLX)

Category

P/E ratio for Renalytix Plc (RNLX)
P/E ratio as of August 2026 TTM: -0.33
According to Renalytix Plc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.33. At the end of 2023 the company had a P/E ratio of -2.63.
P/E ratio history for Renalytix Plc from 2018 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -0.33 -18.54%
2024 -0.41 -84.59%
2023 -2.63 43.09%
2022 -1.84 -94.16%
2021 -31.49 -20.69%
2020 -39.71 484.63%
2019 -6.79 -96.98%
2018 -225.00 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
21.18 -6,439.91%
US
79.49 -23,900.39%
AU
43.15 -13,020.30%
US
-36.43 10,808.26%
US
- -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.